+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cell & Gene Therapy Manufacturing Services Market by Type, Indication, Application, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5591961
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cell & Gene Therapy Manufacturing Services Market grew from USD 17.34 billion in 2023 to USD 19.98 billion in 2024. It is expected to continue growing at a CAGR of 15.81%, reaching USD 48.45 billion by 2030.

Cell and gene therapy manufacturing services represent a burgeoning sector within pharmaceutical and biotechnology industries, focusing on producing techniques that modify genes to treat or prevent diseases. This field’s scope encompasses the development, production, and commercialization of therapies aimed at conditions ranging from genetic disorders to complex cancers. The necessity of these manufacturing services stems from their potential to revolutionize treatment paradigms, offering personalized and potentially curative solutions where traditional treatments fall short. Their applications extend across numerous therapeutic areas including oncology, neurology, and rare genetic disorders, with end uses among pharmaceutical companies, research institutions, and clinical applications.

Market growth is chiefly influenced by technological advancements, increasing incidence of chronic diseases, and supportive regulatory frameworks. Noteworthy is the surge in partnerships and collaborations aimed at enhancing production capabilities and accelerating time-to-market, while significant investment in R&D highlights ongoing innovation. Opportunities exist in optimizing manufacturing processes through automation and AI, which can enhance production efficiency and reduce costs. Furthermore, expansion into emerging markets, where the demand for advanced therapies is rising, presents substantial growth potential.

However, the market faces several limitations, such as high production costs, complex regulatory requirements, and challenges associated with scaling up manufacturing processes. These factors can impede widespread adoption. Additionally, limited availability of skilled personnel and infrastructure barriers pose significant hurdles. Addressing these issues through strategic partnerships and investment in infrastructure will be crucial.

For innovation, the focus might shift towards developing novel delivery systems and improving scalability of gene-editing technologies like CRISPR. Emphasizing research on reducing therapy costs through streamlined production and enhanced supply chain management can drive business growth. Consequently, the market demands agility and strategic foresight, as companies must navigate evolving regulatory landscapes and technological advancements to succeed. The market nature is dynamic, characterized by rapid innovation, competitive interplay, and regulatory scrutiny, requiring continuous adaptation and strategic alignment to capture emerging opportunities.

Understanding Market Dynamics in the Cell & Gene Therapy Manufacturing Services Market

The Cell & Gene Therapy Manufacturing Services Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • High Incidence of Cancer and Other Target Diseases
    • Increasing Investments in Pharmaceutical R&D and Advanced Technologies by CDMOs
    • Focus on the Personalized Medicine with the Rising Tendency Towards Early Disease Diagnosis
  • Market Restraints
    • High Operational Costs Associated With Cell & Gene Therapy Manufacturing Services
  • Market Opportunities
    • Emergence of Advanced Analytical Technologies in Development of Cell & Gene Therapy
    • Improvement in the Supply Chain of Cell & Gene Therapy Manufacturing
  • Market Challenges
    • Quality Control and Contamination Issues in Cell & Gene Therapy Production

Exploring Porter’s Five Forces for the Cell & Gene Therapy Manufacturing Services Market

Porter’s Five Forces framework further strengthens the insights of the Cell & Gene Therapy Manufacturing Services Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cell & Gene Therapy Manufacturing Services Market

External macro-environmental factors deeply influence the performance of the Cell & Gene Therapy Manufacturing Services Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cell & Gene Therapy Manufacturing Services Market

The Cell & Gene Therapy Manufacturing Services Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cell & Gene Therapy Manufacturing Services Market

The Cell & Gene Therapy Manufacturing Services Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Manufacturing Services Market, highlighting leading vendors and their innovative profiles. These include uBriGene Biosciences Inc., Bluebird Bio, Inc., Cell Therapies Pty Ltd., Merck KGaA, Catalent, Inc., Miltenyi Biotec B.V. & Co. KG, Nikon Corporation, Takara Holdings Inc., Charles River Laboratories International, Inc., General Electric Company, Cell and Gene Therapy Catapult, Boehringer Ingelheim International GmbH, c-LEcta GmbH, Advanced BioScience Laboratories, Inc., Thermo Fisher Scientific, Inc., Novartis AG, Cell-Easy SAS, Samsung Biologics Co., Ltd, Recipharm AB, FUJIFILM Diosynth Biotechnologies, Resonac Corporation, Exmoor Pharma Concepts Limited, AGC Biologics, Bio-Techne Corporation, Wuxi Apptec Co., Ltd., Lonza Group, Minaris Regenerative Medicine GmbH, Oxford Biomedica PLC, and F. Hoffmann-La Roche Ltd..

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Manufacturing Services Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Cell Therapy
      • Allogeneic
        • Allogeneic Hematopoietic Stem Cells
        • Allogeneic Induced Pluripotent Stem Cells
        • Allogeneic Mesenchymal Stem Cells
        • Allogeneic Natural Killer Cells
        • Allogeneic T-cells
      • Autologous
        • Autologous Hematopoietic Stem Cells
        • Autologous Mesenchymal Stem Cells
        • Autologous Natural Killer Cells
        • Autologous T-cells
      • Viral Vector
        • Adeno-associated Virus Vectors
        • Retroviral Vectors
    • Gene Therapy
      • Non-viral Vector
      • Oligonucleotides
  • Indication
    • Cardiovascular Diseases
    • Central Nervous System Disorders
    • Infectious Diseases
    • Oncology Diseases
    • Ophthalmology Diseases
    • Orthopedic Diseases
  • Application
    • Clinical Manufacturing
    • Commercial Manufacturing
  • End-User
    • Academic & Research Institutes
    • Pharmaceutical & Biotechnology Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High Incidence of Cancer and Other Target Diseases
5.1.1.2. Increasing Investments in Pharmaceutical R&D and Advanced Technologies by CDMOs
5.1.1.3. Focus on the Personalized Medicine with the Rising Tendency Towards Early Disease Diagnosis
5.1.2. Restraints
5.1.2.1. High Operational Costs Associated With Cell & Gene Therapy Manufacturing Services
5.1.3. Opportunities
5.1.3.1. Emergence of Advanced Analytical Technologies in Development of Cell & Gene Therapy
5.1.3.2. Improvement in the Supply Chain of Cell & Gene Therapy Manufacturing
5.1.4. Challenges
5.1.4.1. Quality Control and Contamination Issues in Cell & Gene Therapy Production
5.2. Market Segmentation Analysis
5.2.1. Type: Applications of autologous mesenchymal stem cells for tissue repair and anti-inflammatory treatments
5.2.2. Indication: Growing potential of oncology therapies for personalized medicine in patients with various malignancies
5.2.3. Application: Significant benefits of customized cell & gene therapy manufacturing services for early-stage products
5.2.4. End-User: Higher preferences for cost-effective services from academic and research institutes
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cell & Gene Therapy Manufacturing Services Market, by Type
6.1. Introduction
6.2. Cell Therapy
6.2.1. Allogeneic
6.2.1.1. Allogeneic Hematopoietic Stem Cells
6.2.1.2. Allogeneic Induced Pluripotent Stem Cells
6.2.1.3. Allogeneic Mesenchymal Stem Cells
6.2.1.4. Allogeneic Natural Killer Cells
6.2.1.5. Allogeneic T-cells
6.2.2. Autologous
6.2.2.1. Autologous Hematopoietic Stem Cells
6.2.2.2. Autologous Mesenchymal Stem Cells
6.2.2.3. Autologous Natural Killer Cells
6.2.2.4. Autologous T-cells
6.2.3. Viral Vector
6.2.3.1. Adeno-associated Virus Vectors
6.2.3.2. Retroviral Vectors
6.3. Gene Therapy
6.3.1. Non-viral Vector
6.3.2. Oligonucleotides
7. Cell & Gene Therapy Manufacturing Services Market, by Indication
7.1. Introduction
7.2. Cardiovascular Diseases
7.3. Central Nervous System Disorders
7.4. Infectious Diseases
7.5. Oncology Diseases
7.6. Ophthalmology Diseases
7.7. Orthopedic Diseases
8. Cell & Gene Therapy Manufacturing Services Market, by Application
8.1. Introduction
8.2. Clinical Manufacturing
8.3. Commercial Manufacturing
9. Cell & Gene Therapy Manufacturing Services Market, by End-User
9.1. Introduction
9.2. Academic & Research Institutes
9.3. Pharmaceutical & Biotechnology Companies
10. Americas Cell & Gene Therapy Manufacturing Services Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cell & Gene Therapy Manufacturing Services Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Fujifilm to Invest USD 200 Million to Expand
13.3.2. eXmoor Pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
13.3.3. Thermo Fisher Scientific Opens Cell Therapy Facility at UCSF to Accelerate Development of Breakthrough Therapies
List of Figures
FIGURE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH PROCESS
FIGURE 2. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET DYNAMICS
TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC NATURAL KILLER CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC T-CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS NATURAL KILLER CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS T-CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY OPHTHALMOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ORTHOPEDIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 74. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 75. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 76. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 77. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 78. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 83. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 84. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 86. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 87. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 114. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 115. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 121. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 122. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 123. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 124. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 125. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 130. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 131. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 132. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 133. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 134. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 141. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 142. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 143. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 148. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 149. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 150. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 151. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 152. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 159. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 160. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 161. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 168. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 169. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 177. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 179. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 185. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 187. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 188. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 194. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 195. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 196. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 197. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 200. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 201. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 202. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 203. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 204. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 205. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 206. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 212. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 213. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 214. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 215. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 228. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 229. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 230. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 231. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 232. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 233. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 234. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 238. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 239. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 240. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 241. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 242. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 243. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 244. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 246. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 247. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 248. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 249. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 250. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 251. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 252. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 253. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 255. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 256. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 257. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 258. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 259. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 260. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 261. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 264. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 265. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 266. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 267. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 268. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 269. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 270. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 271. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
TABLE 277. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
TABLE 278. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 279. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 280. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 282. ITALY CE

Companies Mentioned

The leading players in the Cell & Gene Therapy Manufacturing Services market, which are profiled in this report, include:
  • uBriGene Biosciences Inc.
  • Bluebird Bio, Inc.
  • Cell Therapies Pty Ltd.
  • Merck KGaA
  • Catalent, Inc.
  • Miltenyi Biotec B.V. & Co. KG
  • Nikon Corporation
  • Takara Holdings Inc.
  • Charles River Laboratories International, Inc.
  • General Electric Company
  • Cell and Gene Therapy Catapult
  • Boehringer Ingelheim International GmbH
  • c-LEcta GmbH
  • Advanced BioScience Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • Novartis AG
  • Cell-Easy SAS
  • Samsung Biologics Co., Ltd
  • Recipharm AB
  • FUJIFILM Diosynth Biotechnologies
  • Resonac Corporation
  • Exmoor Pharma Concepts Limited
  • AGC Biologics
  • Bio-Techne Corporation
  • Wuxi Apptec Co., Ltd.
  • Lonza Group
  • Minaris Regenerative Medicine GmbH
  • Oxford Biomedica PLC
  • F. Hoffmann-La Roche Ltd.

Methodology

Loading
LOADING...

Table Information